MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts

Background: Patients with non-small cell lung cancer (NSCLC) initially responding to tyrosine kinase inhibitors (TKIs) eventually develop resistance due to accumulating mutations in the EGFR and additional lesser investigated mechanisms such as the participation of the tumor microenvironment (TME)....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Kaibin, Lv, Zhonghua, Xiong, Jinsheng, Zheng, Hongshan, Zhang, Sibin, Jin, Hua, Yu, Lei, Li, Zhenzhe, Zhang, Jixing, Li, Chenlong, Liang, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993678/
https://www.ncbi.nlm.nih.gov/pubmed/33621951
http://dx.doi.org/10.18632/aging.202547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993678/
https://www.ncbi.nlm.nih.gov/pubmed/33621951
http://dx.doi.org/10.18632/aging.202547

Ejemplares similares